These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. UDCA, PBC and biochemistry: what does normal mean? Lindor KD Gut; 2000 Jan; 46(1):8. PubMed ID: 10601046 [No Abstract] [Full Text] [Related]
25. Practice variation in treatment of primary biliary cirrhosis and effect on clinical outcomes. Talwalkar JA; Gossard AA Hepatology; 2008 Apr; 47(4):1428. PubMed ID: 18366110 [No Abstract] [Full Text] [Related]
26. Pretransplant ursodeoxycholic acid therapy and liver transplantation in patients with primary biliary cirrhosis: win, win, win? Benner KG Liver Transpl Surg; 1999 Jul; 5(4):334-7. PubMed ID: 10388507 [No Abstract] [Full Text] [Related]
27. Treatment with immunosuppressives in patients with primary biliary cirrhosis who fail to respond to ursodiol. Kaplan MM; Poupon R Hepatology; 2009 Aug; 50(2):652. PubMed ID: 19309721 [No Abstract] [Full Text] [Related]
29. Ursodeoxycholic acid in serum and liver tissue in patients with end-stage cholestatic liver cirrhosis. Kita Y; Sakakura H; Hirata M; Harihara Y; Tanaka H; Ito M; Yoshino H; Takayama T; Kubota K; Hashizume K; Makuuchi M Transplant Proc; 1999 Nov; 31(7):2897-8. PubMed ID: 10578330 [No Abstract] [Full Text] [Related]
30. Patients and patience: the pitfalls of primary biliary cirrhosis trials. Mayo MJ Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):552-3. PubMed ID: 16327817 [No Abstract] [Full Text] [Related]
31. Letter: serum vitamin D levels in primary biliary cirrhosis--authors' reply. Guo G; Shi Y; Han Y; Zhou X Aliment Pharmacol Ther; 2015 Sep; 42(5):635. PubMed ID: 26238586 [No Abstract] [Full Text] [Related]
32. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904 [TBL] [Abstract][Full Text] [Related]
33. The use of ursodeoxycholic acid in patients with primary biliary cirrhosis: sense or nonsense. Van Den Bogaert E; Francque S; Pelckmans P; Michielsen P Acta Gastroenterol Belg; 2003; 66(4):283-7. PubMed ID: 14989050 [TBL] [Abstract][Full Text] [Related]
34. Methotrexate for treatment of primary biliary cirrhosis. Bonis PA; Kaplan M Hepatology; 2006 Mar; 43(3):632; author reply 632-3. PubMed ID: 16496314 [No Abstract] [Full Text] [Related]
35. Ursodeoxycholic acid for terbinafine-induced toxic hepatitis. Agca E; Akcay A; Simsek H Ann Pharmacother; 2004 Jun; 38(6):1088-9. PubMed ID: 15122001 [No Abstract] [Full Text] [Related]
36. Effect of ursodeoxycholic acid on chronic intrahepatic cholestasis due to sarcoidosis. Bécheur H; Dall'osto H; Chatellier G; Charton-Bain MC; Aubertin JM; Attar A; Bloch F; Petite JP Dig Dis Sci; 1997 Apr; 42(4):789-91. PubMed ID: 9125650 [No Abstract] [Full Text] [Related]
37. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis. Kuiper EM; Hansen BE; Lesterhuis W; Robijn RJ; Thijs JC; Engels LG; Koek GH; Aparicio MN; Kerbert-Dreteler MJ; van Buuren HR; Clin Res Hepatol Gastroenterol; 2011 Jan; 35(1):29-33. PubMed ID: 20810227 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives. Serfaty L; Poupon R Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S1. PubMed ID: 23141887 [No Abstract] [Full Text] [Related]
39. Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Gómez-Dominguez E; Mendoza J; García-Buey L; Trapero M; Gisbert JP; Jones EA; Moreno-Otero R Aliment Pharmacol Ther; 2008 Mar; 27(5):441-7. PubMed ID: 18081731 [TBL] [Abstract][Full Text] [Related]